NVST Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

680.25M

+4.19%

0.323

+34.5%

652.33M

+5.74%

0.280

+16.52%

703.41M

+3.12%

0.299

+15.02%

Estimates Revision

The market is revising Upward the revenue expectations for Envista Holdings Corporation (NVST) for FY2025, with the revenue forecasts being adjusted by 0.92% over the past three months. During the same period, the stock price has changed by 17.04%.

Revenue Estimates for FY2025

Revise Upward

+0.92%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+2.92%

In Past 3 Month

Stock Price

Go Up

+17.04%

In Past 3 Month

11 Analyst Rating

Wall Street analysts forecast NVST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVST is 22.38 USD with a low forecast of 18.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

6 Hold

1 Sell

Moderate Buy

Current: 0.000

Low

18.00

Averages

22.38

High

27.00

Current: 0.000

Low

18.00

Averages

22.38

High

27.00

JPMorgan

Neutral

maintain

$20 -> $22

2025-12-16

Reason

JPMorgan

Price Target

$20 -> $22

2025-12-16

maintain

Neutral

Reason

JPMorgan raised the firm's price target on Envista to $22 from $20 and keeps a Neutral rating on the shares. The firm updated the company's model.

Stifel

Jonathan Block

Strong Buy

maintain

2025-12-10

Reason

Stifel

Jonathan Block

Price Target

2025-12-10

maintain

Strong Buy

Reason

Stifel analyst Jonathan Block, who hosted meetings with senior management of Envista as part of the firm's West Coast bus tour, reports that management described the current dental market as "stable plus," which is an improvement from the company's prior "stable" and at times "slow, but stable" messaging throughout 2025. The firm, which thought management sounded "upbeat" regarding the overall dental market, keeps a Buy rating on Envista shares.

Barclays

Overweight

initiated

$24

2025-12-08

Reason

Barclays

Price Target

$24

2025-12-08

initiated

Overweight

Reason

Barclays initiated coverage of Envista with an Overweight rating and $24 price target. The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.

Mizuho

analyst

Underperform

maintain

$18 -> $19

2025-11-03

Reason

Mizuho

analyst

Price Target

$18 -> $19

2025-11-03

maintain

Underperform

Reason

Mizuho raised the firm's price target on Envista to $19 from $18 and keeps an Underperform rating on the shares. Envista continued its trend of modest market share gains in Q3 from what the firm believe is a better-positioned product portfolio than broad dental peers, says the analyst, who raised the firm's 2025 and 2026 EPS estimates to reflect the market share gains.

Baird

Outperform

maintain

$25 -> $27

2025-10-31

Reason

Baird

Price Target

$25 -> $27

2025-10-31

maintain

Outperform

Reason

Baird raised the firm's price target on Envista to $27 from $25 and keeps an Outperform rating on the shares. The firm updated its model following solid Q3 results which suggested its core growth recovery remains intact.

Baird

Outperform

maintain

$23 -> $25

2025-08-01

Reason

Baird

Price Target

$23 -> $25

2025-08-01

maintain

Outperform

Reason

Baird raised the firm's price target on Envista to $25 from $23 and keeps an Outperform rating on the shares. The firm updated its model following solid Q2 results driven by solid execution.

Valuation Metrics

The current forward P/E ratio for Envista Holdings Corp (NVST.N) is 17.64, compared to its 5-year average forward P/E of 20.22. For a more detailed relative valuation and DCF analysis to assess Envista Holdings Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

20.22

Current PE

17.64

Overvalued PE

24.29

Undervalued PE

16.15

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

12.80

Current EV/EBITDA

10.87

Overvalued EV/EBITDA

14.95

Undervalued EV/EBITDA

10.66

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

1.91

Current PS

1.31

Overvalued PS

2.48

Undervalued PS

1.33

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

NVST News & Events

Events Timeline

No data

News

9.5

01-08PRnewswire

PinnedEnvista to Report Q4 2025 Financial Results on February 5, 2026

9.5

01-08Newsfilter

Envista to Report Q4 2025 Financial Results on February 5, 2026

1.0

01-07PRnewswire

Envista to Present at J.P. Morgan Healthcare Conference on January 12, 2026

People Also Watch

Frequently Asked Questions

What is Envista Holdings Corp (NVST) stock price today?

The current price of NVST is 23.63 USD — it has increased 0.04 % in the last trading day.

What is Envista Holdings Corp (NVST)'s business?

Envista Holdings Corporation is a global dental products company. The Company's diversified portfolio of solutions covers a range of dentists' clinical needs for preventing, diagnosing, and treating dental conditions as well as improving the aesthetics of the human smile. It has more than 30 dental brands, including Nobel Biocare, Ormco, DEXIS and Kerr. Its segments include Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment primarily develops, manufactures and markets dental implant systems, including regenerative solutions, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. The Equipment & Consumables segment primarily develops, manufactures, and markets dental equipment and supplies used in dental offices, including digital imaging systems, software, and other visualization/magnification systems; and endodontic systems and related products.

What is the price predicton of NVST Stock?

What is Envista Holdings Corp (NVST)'s revenue for the last quarter?

Envista Holdings Corp revenue for the last quarter amounts to 669.90M USD, increased 11.46 % YoY.

What is Envista Holdings Corp (NVST)'s earnings per share (EPS) for the last quarter?

Envista Holdings Corp. EPS for the last quarter amounts to -0.18 USD, decreased -460.00 % YoY.

What changes have occurred in the market's expectations for Envista Holdings Corp (NVST)'s fundamentals?

How many employees does Envista Holdings Corp (NVST). have?

Envista Holdings Corp (NVST) has 12300 emplpoyees as of January 09 2026.

What is Envista Holdings Corp (NVST) market cap?

Today NVST has the market capitalization of 3.88B USD.